July 22, 2020 / 11:03 AM / 20 days ago

Biogen profit rises 3.2% on demand for multiple sclerosis drug

July 22 (Reuters) - Biogen Inc reported a 3.2% rise in second-quarter profit on Wednesday, getting a lift from demand for its top-selling multiple sclerosis drug Tecfidera.

Net income attributable to the company rose to $1.54 billion, or $9.59 per share, in the three months ended June 30 from $1.49 billion, or $7.85 per share, a year earlier. (bit.ly/3jE7NBM)

Total revenue rose to $3.68 billion from $3.62 billion.

Reporting by Trisha Roy and Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below